Cancer treatment trial shows 59.1% response rate in selected lung cancer patients
The response rate applies to a biomarker-selected subgroup, a common design in oncology trials that can limit how broadly results generalize.
Read at Stock Titan →Full coverage · 6 outlets
- Stock Titan · lead
- Yahoo FinanceIovance Biotherapeutics (IOVA) Posts 59.1% Response In Lifileucel Lung Cancer Study
- DealroomIovance's Amtagvi shows 59.1% response in biomarker-selected lung cancer subgroup
- OncodailyBiomarker Landscape of ADCs and Bispecific Antibodies in Lung Cancer: The 2026 Clinical Trial Evidence and Future of Precision Treatment
- GlobeNewswireIovance Biotherapeutics Reports Record Third Quarter 2026
- 2 Minute MedicineIfinatam deruxtecan shows promising efficacy in extensive-stage small-cell lung cancer